Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
14 Translational challenges and opportunities The clinical translation of GSH-responsive nanomedicine faces several important barriers
Adlumiz subsequently approved by the Japan PMDA on January 22, 2021 for cancer cachexia in NSCLC, gastric, pancreatic, and colorectal cancers
QL Biopharm Completes Dosing of First Patient in HORIZON-1, a Phase 3 Trial for Weight Loss with Zovaglutide, a Once-Monthly GLP-1 RA Peptide BEIJING, China, January 19, 2026 On January 16, 2026, Beijing QL Biopharmaceutical Co, Ltd (QL Biopharm) dosed the first patient in its Phase 3 clinical trial, HORIZON-1, which will evaluate QL Biopharms ultra-long-acting GLP-1 receptor agonist (GLP-1 RA), zovaglutide (ZT002)
Role of Lon1 protease in post-germinative growth and maintenance of mitochondrial function in Arabidopsis thaliana
They signal the brain to reduce hunger
US$ 29.40
US$ 23.73
US$ 28.68
US$ 27.95
US$ 29.34
US$ 23.73
US$ 20.96
US$ 22.71
US$ 21.80
US$ 22.69
US$ 28.89
